Insider Buying: Oncolytics Biotech (TSE:ONC) Insider Acquires 12,132 Shares of Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Thomas Heineman acquired 12,132 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of C$1.14 per share, for a total transaction of C$13,830.48. Following the completion of the acquisition, the insider directly owned 168,201 shares of the company’s stock, valued at C$191,749.14. This trade represents a 7.77% increase in their ownership of the stock.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The company’s 50 day simple moving average is C$14.90 and its two-hundred day simple moving average is C$13.02. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. As a group, research analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.